Published in
Taylor and Francis Group, Leukemia & Lymphoma, 13(62), p. 3181-3191, 2021
DOI: 10.1080/10428194.2021.1948029
Links
Tools
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Journal article published in 2021 by
Jonathan A. Webster 
,
Meera Yogarajah,
Marianna Zahurak,
Heather Symons,
Amy E. Dezern,
Ivana Gojo,
Gabrielle T. Prince,
Jillian Morrow,
Richard J. Jones,
B. Douglas Smith,
Margaret Showel
,
Meera Yogarajah,
Marianna Zahurak,
Heather Symons,
Amy E. Dezern,
Ivana Gojo,
Gabrielle T. Prince,
Jillian Morrow,
Richard J. Jones,
B. Douglas Smith,
Margaret Showel
Distributing this paper is prohibited by the publisher
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 